Research summary ·
Prevalence of Y93H resistance-associated substitution in treatment-naïve hepatitis C virus genotype 1b patients: a systematic review and meta-analysis.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This review pooled past work on hepatitis C virus type 1b. It looked at one change in the virus, called Y93H. This change sits in a part of the virus called NS5A. The change may make some virus drugs work less well. All the people tested had not yet had any treatment. The team searched large study lists and combined the data.
What they found
The review took in work on 1,560 untreated people. These people came from Asia and Europe. The Y93H change was found fairly often in them. The results were quite different from one study to the next. Extra checks showed that the pooled result held steady. There were few signs that unpublished work had bent the result.
What it means for patients
The authors say Y93H is a common change in this virus. It shows up on its own, before any treatment. Newer drugs that act on all virus types make it matter less. Even so, the authors say it should still be tracked. They call for the same lab tests to be used everywhere. They say this could help shape care plans and drug policy.
Why it is not certain yet
The results varied a lot between the studies. All the studies came from Asia and Europe. Other parts of the world were not covered. The abstract does not say how the change affected treatment results. A review can only be as good as the studies in it.
Source
Prevalence of Y93H resistance-associated substitution in treatment-naïve hepatitis C virus genotype 1b patients: a systematic review and meta-analysis.
PubMed · PMID 42902253We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Hepatitis C publications